Diabetes Unit, "S. Camillo-Forlanini" Hospital, Rome, Italy.
J Diabetes Sci Technol. 2021 Nov;15(6):1303-1307. doi: 10.1177/1932296820952107. Epub 2020 Aug 29.
Sensor-augmented pumps with predictive low glucose suspend function (PLGS-SAP) help patients avoid hypoglycemia and improve quality of life: in this retrospective study, we investigated long-term effects of PLGS-SAP on metabolic outcomes, acute and chronic diabetic complications, in particular cardiovascular events.
One hundred thirty-nine adults with type 1 diabetes (T1D) treated for more than 10 years with continuous subcutaneous insulin infusion (CSII) were followed for 5 years; 71 (Group 1) started to use PLGS-SAP, and 68 (Group 2) maintained on their non-PLGM insulin pump. Glucose control measures (hemoglobin A1c [HbA1c], acute diabetic complications), clinical outcomes (body mass index [BMI], arterial hypertension, dyslipidemia), chronic diabetes-related complications, and device utilization (continuous glucose monitoring utilization, use of temporary basal rates or special boluses, carbohydrate counting usage) were assessed.
The reduction of HbA1c was significant in Group 1 (from 7.5% ± 1.1% to 7.0% ± 1.0%, = .02), while in Group 2 it did not reach statistical significance (from 7.5% ± 1.1% to 7.4% ± 0.9%, = .853). BMI increased significantly in Group 2 (from 25.3 ± 2.8 to 25.7 ± 3.4, < .001), but not in Group 1 (from 25.2 ± 3.5 to 25.2 ± 2.8, = .887). There were no statistically significant differences in occurrence of acute diabetes complications, other clinical outcomes, prevalence of diabetes-related complications, or device utilization between the groups.
In our five-year follow-up experience with T1D CSII users, PLGS-SAP has resulted efficient in improving metabolic control and maintaining the body weight.
具有预测性低血糖暂停功能（PLGS-SAP）的传感器增强型输液泵有助于患者避免低血糖并提高生活质量：在这项回顾性研究中，我们研究了 PLGS-SAP 对代谢结果、急性和慢性糖尿病并发症（特别是心血管事件）的长期影响。
139 名患有 1 型糖尿病（T1D）的成年人接受了超过 10 年的连续皮下胰岛素输注（CSII）治疗，随访 5 年；71 名（第 1 组）开始使用 PLGS-SAP，68 名（第 2 组）继续使用非 PLGM 胰岛素泵。评估血糖控制措施（血红蛋白 A1c[HbA1c]、急性糖尿病并发症）、临床结局（体重指数[BMI]、动脉高血压、血脂异常）、慢性糖尿病相关并发症和设备使用情况（连续血糖监测使用、临时基础率或特殊推注的使用、碳水化合物计数使用）。
第 1 组的 HbA1c 降低显著（从 7.5%±1.1%降至 7.0%±1.0%， = .02），而第 2 组未达到统计学意义（从 7.5%±1.1%降至 7.4%±0.9%， = .853）。第 2 组的 BMI 显著增加（从 25.3±2.8 增至 25.7±3.4， < .001），但第 1 组没有（从 25.2±3.5 增至 25.2±2.8， = .887）。两组之间急性糖尿病并发症的发生率、其他临床结局、糖尿病相关并发症的患病率或设备使用情况均无统计学差异。
在我们对接受 T1D CSII 治疗的患者进行的五年随访中，PLGS-SAP 有效地改善了代谢控制并保持了体重。
